Last updated: 2026-10-19 07:38:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Oculis Holding AG (OCS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $7.27, with a market capitalization of $448.98M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.11 to $34.48. This page covers its latest market performance, valuation, price trends and company information.
$448.98M | |
$7.33 | |
$34.48 | |
$6.26 | |
$7.40 | |
230.01K | |
264.70K | |
-- | |
$34.48 | |
$7.11 | |
-- | |
-- |
Oculis Holding AG (OCS) last closed at $7.40 as of 2026-10-16 23:31:00, unchanged from the previous close of $7.40.
During the latest regular trading session, OCS traded between $6.26 and $34.48, with a volume of 230.01K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Oculis Holding AG (OCS) moved from $8.66 to $7.27, representing a decline of 16.03% ($1.39).
The stock traded between $7.11 and $8.75 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 369.84 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.6%
OCS is currently trading at $7.27, placing it 0.6% of the way from its 52-week low of $7.11 to its 52-week high of $34.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Oculis Holding AG (OCS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.